TL

Ting-Wan Lin, PhD

Director, Business Development

GenomeFrontier Therapeutics

Therapeutic Areas

GenomeFrontier Therapeutics Pipeline

DrugIndicationPhase
GF-CART01B cell malignanciesPreclinical
GF-CART02Multiple myelomaPreclinical
GF-CART03Solid tumorsPreclinical